The global digital diabetes management market size is expected to reach USD 21.9 billion by 2030, registering a CAGR of 8.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Major factors contributing to the market growth are the growing incidences of diabetes globally, the increasing number of product launches, and innovation in technologies such as predictive analytics and artificial intelligence (AI).
Data analytics and artificial intelligence are now an integral part of digital solutions for diabetics. AI is gaining rapid attention due to its ability to harness massive volumes of patient information. Digital diabetes management tools help patients analyze their glucose levels and pattern. They also help patients decide on food intake and dosage of insulin. The number of smartphone apps for disease management has seen a monumental rise over the past few years, giving the market a major boost. For instance, in September 2019, Abbott entered into a non-exclusive partnership with Sanofi to integrate cloud-connected insulin pens (Sanofi) with FreeStyle Libre mobile application (Abbott) to ease the management process of diabetes.
The market growth is further augmented by the increasing prevalence of obesity, the growing aging population, and increasing awareness regarding diabetes preventive care. Moreover, the market is driven by the increasing number of active users of smart devices and the launch of new apps that allow patients to monitor their blood glucose. These apps use advanced technology for health care professionals and provide patients with better health outcomes. In May 2019, Roche Diabetes Care India introduced its Integrated Diabetes Management Solution (IDMS) program in India with the launch of the Accu-Chek Instant blood glucose monitoring (BGM) system and the My Sugar app. The combination marks the entry of the next-generation BGM system. This is expected to propel the demand for the product, thereby driving the overall market in the country.
Request a free sample copy or view report summary: Digital Diabetes Management Market Report
The continuous glucose monitoring systems segment dominated the market by capturing a share of 40.4% in 2024. CGM systems offer real-time glucose tracking, providing critical insights for both Type 1 and Type 2 diabetes management.
The wearable devices segment held the largest market share in 2024 and is also expected to grow at the fastest CAGR of 8.9% over the forecast period, driven by the increasing demand for convenience, continuous monitoring, and real-time data tracking.
The hospital segment dominated the market by capturing a share of 41.5% in 2024. Hospitals remain the primary setting for diagnostic testing, advanced treatments, and monitoring for patients with severe or complex diabetes.
North America digital diabetes management market held the largest share of 38.2% in 2024. This dominance is driven by the presence of leading market players in the region and the increasing prevalence of diabetes.
Grand View Research has segmented the global digital diabetes management market on the basis of on product, type, end-use and region:
Digital Diabetes Management Product Outlook (Revenue, USD Million, 2018 - 2030)
Smart Glucose Meter
Continuous Blood Glucose Monitoring System
Smart Insulin Pens
Smart Insulin Pumps/Closed Loop Systems
Apps
Digital Diabetes Management Apps
Weight & Diet Management Apps
Digital Diabetes Management Type Outlook (Revenue, USD Million, 2018 - 2030)
Wearable Devices
Handheld Devices
Digital Diabetes Management End Use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Home settings
Diagnostic centers
Digital Diabetes Management Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Italy
Spain
Sweden
Norway
Denmark
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
List of Key Players in the Digital Diabetes Management Market
Abbott
Medtronic
F. Hoffmann-La Roche Ltd.
Bayer AG
Sanofi
Dexcom, Inc.
LifeScan, Inc.
Insulet Corporation
Ascensia Diabetes Care Holdings AG
B. Braun Melsungen AG
"The quality of research they have done for us has been excellent..."